Tucatinib

图卡替尼

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameTucatinib
Drug Alias Name妥卡替尼TucatinibumIrbinitinibTukysaARRY-380 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonistsPhosphorylation inhibitors
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsMetastatic breast cancerGastroesophageal Junction NeoplasmsHepatic Insufficiency +[9] 
Global Approved IndicationsBreast Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2020/04/17
Country/TerritoryCzechiaBelgiumCanada +[34] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesArray Biopharma
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteSeagen IncArray Biopharma +[9] 
Inactive CompaniesCascadian Therapeutics IncUniversity Of Colorado DenverUniversity Of Alabama At Birmingham
Active IndicationsMetastatic breast cancerGastroesophageal Junction NeoplasmsNeoplasm Metastasis +[6] 
Inactive IndicationsHepatic InsufficiencyMeningeal NeoplasmsNeoplasms

Other Information

ATC CodeL01
Related LinksWikipediaDrugBankKEGG